Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Olanzapine
Accession Number
DB00334  (APRD00138)
Type
Small Molecule
Groups
Approved, Investigational
Description

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent.2 The second-generation antipsychotics were introduced in the 90s and quickly widespread due to the presumed higher efficacy, less extrapyramidal side effects and fewer drug-drug interactions.5 Olanzapine presents a very close resemblance to clozapine and it only differs by two additional methyl groups and the absence of a chloride moiety.10 It was obtained by the research of Eli Lilly and approved to be marketed in the US in 1996.8

Structure
Thumb
Synonyms
  • 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
  • Olanzapin
  • Olanzapina
  • Olanzapine
  • Olanzapinum
External IDs
LY 170053 / LY-170053
Product Ingredients
IngredientUNIICASInChI Key
Olanzapine hydrochloride0Q8K2L0MC3783334-36-1MFURKUWVJOJUHP-UHFFFAOYSA-N
Olanzapine pamoateX7S6Q4MHCB221373-18-8ZIMCQJVMPKQQPB-UHFFFAOYSA-N
Olanzapine tartrate0KNI3MFH5F491828-16-1NFEUHAIRXOEOTJ-LREBCSMRSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act OlanzapineTabletOralActavis Pharma Company2009-10-152018-04-30Canada
Act OlanzapineTabletOralActavis Pharma Company2009-10-152018-04-30Canada
Act OlanzapineTabletOralActavis Pharma Company2009-10-152018-04-30Canada
Act OlanzapineTabletOralActavis Pharma Company2009-10-152018-04-30Canada
Act OlanzapineTabletOralActavis Pharma Company2009-10-152018-04-30Canada
Act OlanzapineTabletOralActavis Pharma Company2009-10-152018-04-30Canada
Act Olanzapine ODTTablet, orally disintegratingOralTEVA Canada Limited2009-10-16Not applicableCanada
Act Olanzapine ODTTablet, orally disintegratingOralTEVA Canada Limited2009-10-16Not applicableCanada
Act Olanzapine ODTTablet, orally disintegratingOralTEVA Canada Limited2009-10-16Not applicableCanada
Act Olanzapine ODTTablet, orally disintegratingOralTEVA Canada Limited2009-10-16Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-olanzapine ODTTablet, orally disintegratingOralBgp Pharma Ulc2014-09-172015-12-31Canada
Abbott-olanzapine ODTTablet, orally disintegratingOralAbbott Laboratories2014-12-032015-12-31Canada
Abbott-olanzapine ODTTablet, orally disintegratingOralAbbott2014-09-172015-12-31Canada
Accel-olanzapineTabletOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTabletOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTabletOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTabletOralAccel Pharma IncNot applicableNot applicableCanada
Accel-olanzapineTabletOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTabletOralAccel Pharma Inc2014-09-042015-11-09Canada
Ag-olanzapine FcTabletOralAngita Pharma Inc.Not applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine hydrochloride (25 mg/1)CapsuleOralPar Pharmaceutical, Inc.2012-11-26Not applicableUs
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine hydrochloride (25 mg/1)CapsuleOralAvKARE, Inc.2014-01-21Not applicableUs00093 5506 56 nlmimage10 1e270f18
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine hydrochloride (25 mg/1)CapsuleOralTeva2012-06-19Not applicableUs0093 550620180913 8702 1lzk1pa
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine hydrochloride (50 mg/1)CapsuleOralPar Pharmaceutical, Inc.2012-11-26Not applicableUs
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine hydrochloride (25 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine hydrochloride (50 mg/1)CapsuleOralAvKARE, Inc.2014-01-21Not applicableUs00093 5505 56 nlmimage10 f426fa17
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine hydrochloride (50 mg/1)CapsuleOralTeva2012-06-19Not applicableUs0093 550520180913 8702 o1l3y5
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine hydrochloride (25 mg/1)CapsuleOralPar Pharmaceutical, Inc.2012-11-26Not applicableUs
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine hydrochloride (50 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine hydrochloride (25 mg/1)CapsuleOralAvKARE, Inc.2014-01-21Not applicableUs00093 5504 56 nlmimage10 292714e8
International/Other Brands
Aedon (G.L. Pharma) / Amulsin (Sanitas) / Apisco (LKM) / Apsico (LKM) / Arkolamyl (Mylan) / Caprilon (Lavipharm) / CO Olanzapine (Cobalt) / Deprex (Square) / Dominazol (Stein) / Dopin (Daksh) / Egolanza (EGIS) / Elynza (Elynza) / Frenial (Biogen) / Jolyon-MD (Lupin) / Kozylex (Quisisana) / Lanopin (Molekule) / Lanzapin (Biogened) / Lanzep (Renata) / Lapenza (Smart Intermed) / Lapozan (Medochemie) / Lazapix (Portfarma)
Categories
UNII
N7U69T4SZR
CAS number
132539-06-1
Weight
Average: 312.432
Monoisotopic: 312.14086735
Chemical Formula
C17H20N4S
InChI Key
KVWDHTXUZHCGIO-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
IUPAC Name
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2

Pharmacology

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.6

Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.Label

As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.6

Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.Label

Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.11

Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.12

Associated Conditions
Pharmacodynamics

The effect of olanzapine in the D2 receptor is reported to produce the positive effects of this drug such as a decrease in hallucinations, delusions, disorganized speech, disorganized thought, and disorganized behavior. On the other hand, its effect on the serotonin 5HT2A receptor prevents the onset of anhedonia, flat affect, alogia, avolition and poor attention.6 Based on the specific mechanism of action, olanzapine presents a higher affinity for the dopamine D2 receptor when compared to the rest of the dopamine receptor isotypes. This characteristic significantly reduces the presence of side effects.10

Clinical trials for the original use of olanzapine demonstrated significant effectiveness in the treatment of schizophrenia and bipolar disorder in adults and acute manic or mixed episodes associated with bipolar disorder in adolescents.4

The effect of olanzapine on dopamine and serotonin receptors has been suggested to reduce chemotherapy-induced nausea and vomiting as those receptors are suggested to be involved in this process. For this effect, several clinical trials have been conducted and it has been shown that olanzapine can produce a significant increase in total control of nausea and vomiting.1 In a high-level study of the effect of olanzapine for this condition, a complete response on the delay phase was observed in 84% of the individual and control of emesis of over 80% despite the phase.3

Mechanism of action

The activity of olanzapine is achieved by the antagonism of multiple neuronal receptors including the dopamine receptor D1, D2, D3 and D4 in the brain, the serotonin receptors 5HT2A, 5HT2C, 5HT3 and 5HT6, the alpha-1 adrenergic receptor, the histamine receptor H1 and multiple muscarinic receptors.1,3

As abovementioned, olanzapine presents a wide profile of targets, however, its antagonistic effect towards the dopamine D2 receptor in the mesolimbic pathway is key as it blocks dopamine from having a potential action at the post-synaptic receptor. The binding of olanzapine to the dopamine D2 receptors is easily dissociable and hence, it allows for a certain degree of dopamine neurotransmission.6

On the other hand, olanzapine acts in the serotonin 5HT2A receptors in the frontal cortex in a similar manner than the reported on dopamine D2 receptors. This determined effect allows for a decrease in adverse effects.6

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Humans
ADopamine D2 receptor
antagonist
Humans
UDopamine D1 receptor
antagonist
Humans
UDopamine D5 receptor
antagonist
Humans
UDopamine D3 receptor
antagonist
Humans
UDopamine D4 receptor
antagonist
Humans
U5-hydroxytryptamine receptor 2C
antagonist
Humans
U5-hydroxytryptamine receptor 3A
antagonist
Humans
U5-hydroxytryptamine receptor 6
antagonist
Humans
UHistamine H1 receptor
antagonist
Humans
UAlpha-1A adrenergic receptor
antagonist
Humans
UAlpha-1B adrenergic receptor
antagonist
Humans
UMuscarinic acetylcholine receptor M1
antagonist
Humans
UMuscarinic acetylcholine receptor M2
antagonist
Humans
UMuscarinic acetylcholine receptor M3
antagonist
Humans
UMuscarinic acetylcholine receptor M4
antagonist
Humans
UD(1) dopamine receptor
antagonist
Humans
NBeta adrenergic receptor
inhibitor
Humans
U5-hydroxytryptamine receptor 1
inhibitor
Humans
NGABA-A receptor (benzodiazepine site)
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Olanzapine presents a linear pharmacokinetic profile and, after daily administration, it reaches steady-state in about a week.6 Under the administration of a normal dosage of olanzapine, the steady-state plasma concentration does not seem to exceed 150 ng/ml with an AUC of 333 ng/h/ml.7,10

The absorption of olanzapine is not affected by the concomitant administration of food. The pharmacokinetic profile of olanzapine is characterized by reaching peak plasma concentration of 156.9 ng/ml approximately 6 hours after oral administration.8

Volume of distribution

The volume of distribution of olanzapine is reported to be of 1000 liters which indicate a large distribution throughout the body.6

Protein binding

Olanzapine is largely bound to plasma proteins and hence, about 93% of the administered dose is bound. The main proteins for binding are albumin and alpha-1 acid glycoprotein.6

Metabolism

Olanzapine is greatly metabolized in the liver, which represents around 40% of the administered dose, mainly by the activity of glucuronide enzymes and by the cytochrome P450 system. From the CYP system, the main metabolic enzymes are CYP1A2 and CYP2D6.6 As part of the phase I metabolism, the major circulating metabolites of olanzapine, accounting for approximate 50-60% of this phase, are the 10-N-glucuronide and the 4'-N-desmethyl olanzapine which are clinically inactive and formed by the activity of CYP1A2.8 On the other hand, CYP2D6 catalyzes the formation of 2-OH olanzapine and the flavin-containing monooxygenase (FMO3) is responsible for N-oxide olanzapine.9

On the phase II metabolism of olanzapine, UGT1A4 is the key player by generating direct conjugation forms of olanzapine.9

Route of elimination

Olanzapine is mainly eliminated through metabolism and hence, only 7% of the eliminated drug can be found as the unchanged form. It is mainly excreted in the urine which represents around 53% of the excreted dose followed by the feces that represent about 30%.6

Half life

Olanzapine presents a half-life ranging between 21 to 54 hours with an average half-life of 30 hours.6

Clearance

The mean clearance rate of olanzapine is of 29.4 L/hour however, some studies have reported an apparent clearance of 25 L/h.10

Toxicity

The toxicity symptoms of olanzapine are known to include somnolence, mydriasis, blurred vision, respiratory depression, hypotension, extrapyramidal symptoms and anticholinergic effects. The overdosage effects in children are generally associated with more significant side effects.7

The maximum registered dosage of olanzapine in clinical trials was of 300 mg and it was reported to present drowsiness and slurred speech. However, on post-marketing surveillance, a wide range of symptoms have been presented including agitation, dysarthria, tachycardia, extrapyramidal symptoms, and reduced consciousness. One case of overdosage-driven death was reported after ingestion of 450 mg of olanzapine. In the cases of acute overdosage, the establishment of adequate oxygenation and ventilation, gastric lavage and administration of activated charcoal with a laxative is recommended.Label

In carcinogenesis studies, olanzapine was showed to present an increase in the incidence of liver hemangiomas and hemangiosarcomas as well as mammary gland adenomas, and adenocarcinomas. On fertility studies, there was solely found impairment in male mating performance and delays in ovulation. There is no evidence of mutagenic, genotoxic potential not adverse events on fertility.Label

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
5-hydroxytryptamine receptor 1A---(C;C)CC Allele (homozygous)Effect Directly StudiedThe presence of this polymorphism in HTR1A may indicate a higher level of efficacy in improving negative symptoms of schizophrenia when treated with olanzapine.Details

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Olanzapine.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Olanzapine.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidineThe metabolism of Olanzapine can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
1,10-PhenanthrolineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with 1,10-Phenanthroline.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Olanzapine.
2,5-Dimethoxy-4-ethylamphetamineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,5-DinitrocatecholThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Olanzapine.
4-Bromo-2,5-dimethoxyamphetamineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.
4-Bromo-2,5-dimethoxyphenethylamineThe therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Olanzapine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference
US6020487
General References
  1. Chelkeba L, Gidey K, Mamo A, Yohannes B, Matso T, Melaku T: Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract (Granada). 2017 Jan-Mar;15(1):877. doi: 10.18549/PharmPract.2017.01.877. Epub 2017 Mar 15. [PubMed:28503222]
  2. Martel ML, Klein LR, Rivard RL, Cole JB: A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department. Acad Emerg Med. 2016 Jan;23(1):29-35. doi: 10.1111/acem.12842. Epub 2015 Dec 31. [PubMed:26720055]
  3. Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y: Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul;83(7):1369-1379. doi: 10.1111/bcp.13242. Epub 2017 Mar 23. [PubMed:28112422]
  4. Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC: Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013 Aug 1;14:38. doi: 10.1186/2050-6511-14-38. [PubMed:23902726]
  5. Malhotra K, Vu P, Wang DH, Lai H, Faziola LR: Olanzapine-Induced Neutropenia. Ment Illn. 2015 Jun 23;7(1):5871. doi: 10.4081/mi.2015.5871. eCollection 2015 Feb 24. [PubMed:26266027]
  6. Thomas K, Saadabadi A: Olanzapine . [PubMed:30422498]
  7. Chue P, Singer P: A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci. 2003 Jul;28(4):253-61. [PubMed:12921220]
  8. Green W. (2001). Child & adolescent clinical psychopharmacology (3rd ed.). Lippincott Williams & Wilkins. [ISBN:0-7817-5950-1]
  9. Ng C., Lin K., Singh B. and Chiu E. (2008). Ethno-psychopharmacology. Cambridge University Press. [ISBN:978-0-521-87363-5]
  10. Schatzberg A. and Nemeroff C. (2017). The american psychiatric association publishing textbook of psychopharmacology (5th ed.). American Psychiatric Association Publishing. [ISBN:978-161-5371-228]
  11. Canadian Mental Health Association [Link]
  12. NIH [Link]
  13. Mylan-Olanzapine. Product monograph [Link]
External Links
Human Metabolome Database
HMDB0005012
KEGG Drug
D00454
KEGG Compound
C07322
PubChem Compound
4585
PubChem Substance
46507666
ChemSpider
10442212
BindingDB
35254
ChEBI
7735
ChEMBL
CHEMBL715
Therapeutic Targets Database
DAP000022
PharmGKB
PA450688
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Olanzapine
ATC Codes
N05AH03 — Olanzapine
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (418 KB)
MSDS
Download (232 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingOtherAdverse Effect of Other Antipsychotics and Neuroleptics / Insulin Resistance1
1CompletedNot AvailableHealthy Volunteers4
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceNormal Non-fluency1
1CompletedTreatmentAcute Agitation1
1CompletedTreatmentCancer, Advanced / Weight Loss1
1CompletedTreatmentDyskinesia, Drug-Induced1
1CompletedTreatmentFasting2
1CompletedTreatmentFed2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentMood Disorders With Psychotic Features / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders3
1Not Yet RecruitingBasic ScienceHealthy Controls1
1RecruitingDiagnosticSchizophrenic Disorders1
1RecruitingPreventionAntipsychotic-induced Weight Gain1
1RecruitingTreatmentHealthy Volunteers1
1TerminatedNot AvailableHealthy Volunteers1
1, 2CompletedTreatmentSchizophrenic Disorders3
1, 2CompletedTreatmentSubjects Had Unipolar, Non-psychotic Major Depression1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
2Active Not RecruitingTreatmentSchizophrenic Disorders1
2CompletedPreventionPost Operative Nausea and Vomiting (PONV)1
2CompletedSupportive CareChemotherapy-Induced Nausea and Vomiting (CINV)1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAlcohol Use Disorder (AUD) / Schizophrenic Disorders1
2CompletedTreatmentAnorexia Nervosa (AN)1
2CompletedTreatmentAutistic Disorder1
2CompletedTreatmentEating Disorders1
2CompletedTreatmentSchizophrenic Disorders18
2Not Yet RecruitingTreatmentMalignancies1
2RecruitingSupportive CareEnd Stage Cancer / Nausea / Vomiting1
2RecruitingSupportive CareHematopoietic System--Cancer / Nausea / Vomiting in Infants and/or Children1
2RecruitingTreatmentChemotherapy-Induced Nausea and Vomiting (CINV) / Nausea / Vomiting1
2RecruitingTreatmentMalignant Neoplasm of Stomach1
2TerminatedSupportive CareVomiting1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
2Unknown StatusSupportive CareChemotherapy-Induced Nausea and Vomiting (CINV)1
2Unknown StatusSupportive CareNausea / Vomiting1
2WithdrawnTreatmentGerm Cell Tumors1
2WithdrawnTreatmentSchizophrenic Disorders1
2, 3CompletedTreatmentAutism, Early Infantile1
2, 3RecruitingBasic ScienceHealthy Volunteers1
2, 3RecruitingPreventionNausea, Postoperative / Post Operative Nausea and Vomiting (PONV)1
2, 3RecruitingTreatmentCancer, Advanced1
2, 3TerminatedTreatmentSchizophrenic Disorders1
2, 3Unknown StatusTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2, 3WithdrawnTreatmentDiabetes Mellitus (DM)1
3Active Not RecruitingSupportive CareHematopoietic/Lymphoid Cancer / Nausea and vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3Active Not RecruitingTreatmentBreast Cancer2
3Active Not RecruitingTreatmentSchizophrenic Disorders1
3CompletedPreventionSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedPreventionWeight Gain1
3CompletedSupportive CareChemotherapy-Induced Nausea and Vomiting (CINV)1
3CompletedSupportive CareComplications of Bone Marrow Transplant / Neoplasms, Hematologic1
3CompletedTreatmentAcute Schizophrenia1
3CompletedTreatmentAgitation / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentAlcohol Dependence1
3CompletedTreatmentBipolar Disorder (BD)8
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar Disorder I or II1
3CompletedTreatmentBipolar I Disorder3
3CompletedTreatmentBorderline Personality Disorder (BPD)2
3CompletedTreatmentDepression, Bipolar1
3CompletedTreatmentDevelopmental Delay Disorders / Mental Retardation1
3CompletedTreatmentHuntington's Disease (HD)1
3CompletedTreatmentLennox-Gastaut Syndrome (LGS)1
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentMajor Depressive Disorder With Psychotic Features1
3CompletedTreatmentManic or Mixed Episode Associated With Bipolar I Disorder1
3CompletedTreatmentMental Health / Psychiatric Disorder NOS / Psychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentPathological Gambling1
3CompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders2
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders3
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders27
3CompletedTreatmentTreatment Resistant Depression (TRD)1
3RecruitingPreventionChemotherapy-Induced Nausea and Vomiting (CINV)2
3RecruitingSupportive CareCarcinoma, Breast1
3RecruitingSupportive CareNausea / Vomiting1
3RecruitingSupportive CareNeoplasms, Malignant1
3RecruitingTreatmentAntiemetic for Highly Emetogenic Chemotherapy1
3RecruitingTreatmentBipolar I Disorder / Schizophrenic Disorders / Schizophreniform Disorders1
3TerminatedPreventionSchizophrenic Disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD)1
3TerminatedTreatmentEating Disorder1
3TerminatedTreatmentNausea / Neoplasms1
3TerminatedTreatmentTherapy-Resistant Depression1
3TerminatedTreatmentTreatment Resistant Depression (TRD)1
3TerminatedTreatmentTreatment-resistant Schizophrenia1
3Unknown StatusTreatmentPsychosis Nos/Other1
3WithdrawnTreatmentRelapse Rate of a Major Depressive Episode / Safety of Olanzapine in Subjects With Major Depression1
3WithdrawnTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4Active Not RecruitingDiagnosticFirst Episode Psychosis / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedNot AvailableHealthy Male Volunteers1
4CompletedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedBasic ScienceDiabetes Mellitus (DM)2
4CompletedBasic ScienceDiabetes Mellitus (DM) / Schizophrenic Disorders1
4CompletedBasic ScienceSchizophrenic Disorders / Sleep1
4CompletedDiagnosticMajor Depressive Disorder (MDD)1
4CompletedPreventionBipolar Disorder (BD)1
4CompletedPreventionSchizophrenic Disorders2
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Alzheimer Type / Dementias / Senile Dementia, Alzheimer Type1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Schizophrenic Disorders1
4CompletedTreatmentAnorexia Nervosa (AN)1
4CompletedTreatmentAnxiety Disorders / Moods Disorders / Schizophrenic Disorders1
4CompletedTreatmentAggressive reaction / Attention Deficit Disorder With Hyperactivity (ADHD) / Attention Deficit-Hyperactivity / Bipolar Disorder (BD) / Oppositional Defiant Disorder / PDD / Pervasive Development Disorders1
4CompletedTreatmentBipolar Disorder (BD)11
4CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar1
4CompletedTreatmentBipolar Disorder (BD) / Depression / Depressive Disorders1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar Disorder (BD) / Schizoaffective Disorders1
4CompletedTreatmentBipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentBipolar I Disorder1
4CompletedTreatmentBipolar I Disorder / Schizophrenic Disorders1
4CompletedTreatmentBipolar Spectrum Disorder1
4CompletedTreatmentDementias1
4CompletedTreatmentDepression, Bipolar3
4CompletedTreatmentDepression / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentDiabetes Mellitus (DM) / Hyperglycemia / Metabolic Syndromes / Schizophrenic Disorders1
4CompletedTreatmentDiabetes Mellitus (DM) / Schizophrenic Disorders1
4CompletedTreatmentEarly-onset Schizophrenia1
4CompletedTreatmentEating Disorders1
4CompletedTreatmentEmergency Psychiatric / Psychiatric Disorders / Psychomotor Agitation / Tranquilizers1
4CompletedTreatmentExtrapyramidal disorder / Schizophrenic Disorders1
4CompletedTreatmentHeadache1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentNeurocognitive Function / Tardive Dyskinesia1
4CompletedTreatmentNeuroleptic-Induced Tardive Dyskinesia1
4CompletedTreatmentObsessive Compulsive Disorder (OCD)1
4CompletedTreatmentPsychotic Depression1
4CompletedTreatmentPsychotic Disorder NOS2
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenia, Childhood / Schizophrenic Disorders1
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders2
4CompletedTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders8
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder3
4CompletedTreatmentSchizophrenic Disorders28
4CompletedTreatmentTrichotillomania1
4CompletedTreatmentWeight Gain1
4Not Yet RecruitingTreatmentPsychosis / Substance Use Disorder (SUD)1
4Not Yet RecruitingTreatmentSchizophrenic Disorders1
4RecruitingBasic ScienceHealthy Volunteers1
4RecruitingTreatmentAcute Agitation, Behavioural Emergency1
4RecruitingTreatmentAcute Agitation / Behavioural Emergency1
4RecruitingTreatmentBipolar Disorder (BD)2
4RecruitingTreatmentChemotherapy-Induced Nausea and Vomiting (CINV) / Lung Cancers1
4RecruitingTreatmentSchizophrenic Disorders1
4TerminatedPreventionDepression1
4TerminatedTreatmentAcute Mania / Bipolar Disorder, Manic1
4TerminatedTreatmentBipolar Disorder (BD)2
4TerminatedTreatmentMetabolic Syndromes / Schizophrenic Disorders1
4TerminatedTreatmentSchizophrenic Disorders2
4Unknown StatusTreatmentSchizophrenia or Schizoaffective Disorder1
4Unknown StatusTreatmentSchizophrenic Disorders1
4WithdrawnPreventionSchizoaffective Disorders / Schizophrenic Disorders1
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentBipolar Disorder (BD)1
Not AvailableActive Not RecruitingTreatmentBipolar Disorder (BD) / BMI >30 kg/m2 / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableAnorexia Nervosa (AN) / Attention Deficit Disorder With Hyperactivity (ADHD) / Depression1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableDyslipidemias / Insulin Resistance1
Not AvailableCompletedNot AvailableLactic Acidosis / Movement Disorders1
Not AvailableCompletedNot AvailablePsychomotor Agitation1
Not AvailableCompletedNot AvailableSchizophrenic Disorders2
Not AvailableCompletedBasic ScienceDiabetes Mellitus (DM) / Insulin Resistance1
Not AvailableCompletedBasic ScienceDiabetes Mellitus (DM) / Insulin Resistance / Schizophrenic Disorders1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceSchizophrenic Disorders1
Not AvailableCompletedPreventionDelirium1
Not AvailableCompletedPreventionHyperglycemia / Hyperlipidemias1
Not AvailableCompletedPreventionWeight Gain1
Not AvailableCompletedScreeningBMI >30 kg/m2 / Diabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAnorexia Nervosa (AN)1
Not AvailableCompletedTreatmentAnorexia Nervosa (AN) / Bulimia Nervosa1
Not AvailableCompletedTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD) / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedTreatmentBorderline Personality Disorder (BPD)1
Not AvailableCompletedTreatmentCancer, Advanced1
Not AvailableCompletedTreatmentCancer, Advanced / Delirium1
Not AvailableCompletedTreatmentDelusional Disorder / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedTreatmentHyperglycemia / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentPsychomotor Agitation1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableCompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedTreatmentSchizophrenic Disorders6
Not AvailableCompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus2
Not AvailableCompletedTreatmentSubstance Withdrawal Syndrome1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableEnrolling by InvitationPreventionChemotherapy-Induced Nausea and Vomiting (CINV)1
Not AvailableNot Yet RecruitingBasic ScienceSchizophrenia, Bipolar Disorder1
Not AvailableRecruitingNot AvailableAdverse Drug Effect of Antipsychotics and Neuroleptics / Efficacy / Individualed Opitmal Therapy / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableMicrognathia / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableRecruitingTreatmentSchizophrenic Disorders1
Not AvailableTerminatedNot AvailablePsychomotor Agitation1
Not AvailableTerminatedTreatmentAgitation / Delirium1
Not AvailableTerminatedTreatmentBipolar Disorder (BD) / Psychotic Disorder NOS1
Not AvailableTerminatedTreatmentIdiopathic Gastroparesis1
Not AvailableTerminatedTreatmentSchizophrenic Disorders1
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusSupportive CareSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders2
Not AvailableWithdrawnNot AvailableNausea / Vomiting1
Not AvailableWithdrawnSupportive CareHematopoietic/Lymphoid Cancer / Pain / Unspecified Adult Solid Tumor, Protocol Specific1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
Packagers
  • Advanced Pharmaceutical Services Inc.
  • AQ Pharmaceuticals Inc.
  • Block Drug Co. Inc.
  • Cardinal Health
  • Catalent Pharma Solutions
  • Comprehensive Consultant Services Inc.
  • Dispensing Solutions
  • Eli Lilly & Co.
  • Heartland Repack Services LLC
  • Lake Erie Medical and Surgical Supply
  • Lilly Del Caribe Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neuman Distributors Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Stat Rx Usa
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntramuscular10 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular10 mg/2mL
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral7.5 mg/1
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral20 mg/1
Tablet, orally disintegratingOral5 mg/1
CapsuleOral
Tablet, film coatedOral10 mg
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral5 mg
Tablet, film coatedOral7.5 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral15 mg
Tablet, orally disintegratingOral20 mg
Tablet, orally disintegratingOral5 mg
Powder, for solutionIntramuscular
TabletOral10 mg
TabletOral15 mg
TabletOral2.5 mg
TabletOral20 mg
TabletOral5 mg
TabletOral7.5 mg
Tablet, coatedOral10 mg
Tablet, coatedOral15 mg
Tablet, coatedOral2.5 mg
Tablet, coatedOral5 mg
Tablet, coatedOral7.5 mg
Tablet, film coatedOral15 mg
Tablet, film coatedOral20 mg
Tablet, orally disintegratingOral7.5 mg
Tablet, orally disintegratingOral
Injection, powder, for suspension, extended releaseIntramuscular210 mg
Injection, powder, for suspension, extended releaseIntramuscular300 mg
Injection, powder, for suspension, extended releaseIntramuscular405 mg
Injection, powder, for solutionIntramuscular10 mg
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
TabletOral7.5 mg/1
Tablet, coatedOral20 mg
TabletOral
Powder, for solutionIntramuscular10 mg
KitIntramuscular210 mg/1.4mL
KitIntramuscular300 mg/2.0mL
KitIntramuscular405 mg/2.7mL
Prices
Unit descriptionCostUnit
Zyprexa relprevv 405 mg vial1287.9USD vial
Zyprexa relprevv 300 mg vial954.0USD vial
Zyprexa relprevv 210 mg vial667.8USD vial
ZyPREXA Zydis 30 10 mg Dispersible Tablet Box562.35USD box
ZyPREXA Zydis 30 5 mg Dispersible Tablet Box385.63USD box
Zyprexa 10 mg vial35.69USD vial
Zyprexa zydis 20 mg tablet34.87USD tablet
Zyprexa 20 mg tablet34.37USD tablet
Zyprexa zydis 15 mg tablet26.45USD tablet
Zyprexa 15 mg tablet21.14USD tablet
Symbyax 12-25 mg capsule20.62USD capsule
Symbyax 12-50 mg capsule20.62USD capsule
Zyprexa zydis 10 mg tablet18.02USD tablet
Symbyax 6-50 mg capsule14.56USD capsule
Zyprexa 10 mg tablet14.09USD tablet
Symbyax 6-25 mg capsule13.69USD capsule
Zyprexa zydis 5 mg tablet12.36USD tablet
Zyprexa 7.5 mg tablet11.23USD tablet
Symbyax 3-25 mg capsule10.01USD capsule
Zyprexa 5 mg tablet8.92USD tablet
Zyprexa Zydis 10 mg Disintegrating Tablet7.86USD tablet
Zyprexa 2.5 mg tablet7.1USD tablet
Apo-Olanzapine 15 mg Tablet6.64USD tablet
Co Olanzapine 15 mg Tablet6.64USD tablet
Novo-Olanzapine 15 mg Tablet6.64USD tablet
Pms-Olanzapine 15 mg Tablet6.64USD tablet
Apo-Olanzapine 10 mg Tablet4.43USD tablet
Co Olanzapine 10 mg Tablet4.43USD tablet
Novo-Olanzapine 10 mg Tablet4.43USD tablet
Pms-Olanzapine 10 mg Tablet4.43USD tablet
Zyprexa Zydis 5 mg Disintegrating Tablet3.93USD tablet
Co Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Novo-Olanzapine Od 10 mg Disintegrating Tablet3.54USD tablet
Pms-Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Sandoz Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Apo-Olanzapine 7.5 mg Tablet3.32USD tablet
Co Olanzapine 7.5 mg Tablet3.32USD tablet
Novo-Olanzapine 7.5 mg Tablet3.32USD tablet
Pms-Olanzapine 7.5 mg Tablet3.32USD tablet
Apo-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine 5 mg Tablet2.21USD tablet
Novo-Olanzapine 5 mg Tablet2.21USD tablet
Pms-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Novo-Olanzapine Od 5 mg Disintegrating Tablet1.77USD tablet
Pms-Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Sandoz Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Apo-Olanzapine 2.5 mg Tablet1.11USD tablet
Co Olanzapine 2.5 mg Tablet1.11USD tablet
Novo-Olanzapine 2.5 mg Tablet1.11USD tablet
Pms-Olanzapine 2.5 mg Tablet1.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6251895No2001-06-262018-03-23Us
US5229382No1993-07-202011-04-23Us
CA2216372No2007-11-202016-03-22Canada
CA2041113No1998-07-142011-04-24Canada
US6960577No2005-11-012017-11-01Us
US5945416No1999-08-312017-03-24Us
US6169084No2001-01-022018-09-30Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)189-195 °C'MSDS'
boiling point (°C)476 ºC'MSDS'
water solubilityPartly miscible 'MSDS'
logP4.094'MSDS'
pKa10.57Mylan-Olanzapine product monograph
Predicted Properties
PropertyValueSource
Water Solubility0.0942 mg/mLALOGPS
logP3.61ALOGPS
logP3.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.17ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity93.87 m3·mol-1ChemAxon
Polarizability35.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.9652
Caco-2 permeable+0.5993
P-glycoprotein substrateSubstrate0.8524
P-glycoprotein inhibitor IInhibitor0.6888
P-glycoprotein inhibitor IIInhibitor0.7204
Renal organic cation transporterInhibitor0.7715
CYP450 2C9 substrateNon-substrate0.7493
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5421
CYP450 1A2 substrateInhibitor0.6454
CYP450 2C9 inhibitorNon-inhibitor0.6914
CYP450 2D6 inhibitorInhibitor0.608
CYP450 2C19 inhibitorInhibitor0.572
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.707
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.9369
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.7569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0009000000-256a6e976b00468fe839
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0049000000-83ee647255e8d18f2b5c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090000000-81810b42dccae4ee9ab6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0bt9-0490000000-8994262c6a309d663713
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ot-0950000000-ceb0ca01cefbd1da57d7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0149000000-e74851873e2fbaa6c182
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dj-0940000000-1103f40c5bb833e12903
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dj-0940000000-37cb2e8fb99c38b097b8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0149000000-338b982664cf3019be13
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-2790000000-bdc5a34b08715b752eef

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
Not Available
Direct Parent
Benzodiazepines
Alternative Parents
Thienodiazepines / 2,3,5-trisubstituted thiophenes / N-methylpiperazines / N-arylated-2-aminothiophenes / 1,4-diazepines / Imidolactams / Benzenoids / Heteroaromatic compounds / Trialkylamines / Secondary amines
show 5 more
Substituents
Benzodiazepine / Thieno-para-diazepine / 2,3,5-trisubstituted thiophene / Para-diazepine / N-methylpiperazine / N-alkylpiperazine / N-arylated-2-aminothiophene / 1,4-diazinane / Piperazine / 2-aminothiophene
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, N-methylpiperazine, benzodiazepine (CHEBI:7735)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA: Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9. [PubMed:14530903]
  2. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, Lucignani G, Colombo C, Rizzo G, Velona I, Smeraldi E, Fazio F: Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004 Sep;18(3):355-65. [PubMed:15358979]
  3. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ: Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005 Apr;66(4):450-4. [PubMed:15816787]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601]
  5. Padin JF, Rodriguez MA, Dominguez E, Dopeso-Reyes IG, Buceta M, Cano E, Sotelo E, Brea J, Caruncho HJ, Isabel Cadavid M, Castro M, Isabel Loza M: Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology. 2006 Sep;51(4):923-32. Epub 2006 Aug 14. [PubMed:16905159]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  9. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  10. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Details
2. Dopamine D2 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800]
  4. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T: In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol. 2007 Aug;21(6):620-7. Epub 2006 Nov 8. [PubMed:17092971]
  5. Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, Brown RW: The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci. 2006 Oct;24(7):2075-83. [PubMed:17067304]
  6. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006 Mar;163(3):529-31. [PubMed:16513877]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  9. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Details
3. Dopamine D1 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  4. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Details
4. Dopamine D5 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Details
5. Dopamine D3 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Details
6. Dopamine D4 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R: The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006 Jun;31(6):1310-7. [PubMed:16237394]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006 Feb 14;71(4):521-9. Epub 2005 Dec 5. [PubMed:16336943]
  3. Overstreet DH, Knapp DJ, Breese GR: Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res. 2007 Sep;31(9):1473-81. Epub 2007 Jul 11. [PubMed:17624999]
  4. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J: No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. Epub 2006 Sep 19. [PubMed:16983399]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396]
  6. Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. [PubMed:16952163]
  7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  8. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Details
10. Histamine H1 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A: The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20(2):101-3. [PubMed:15729086]
  3. Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL: Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9- diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J Pharmacol Exp Ther. 2005 Dec;315(3):1265-77. Epub 2005 Sep 1. [PubMed:16141369]
  4. Altschuler EL, Kast RE: Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses. 2005;65(1):65-7. [PubMed:15893120]
  5. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  6. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  7. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  3. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  4. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  4. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
  3. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
  4. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein group
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]
Kind
Protein group
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. [PubMed:25032030]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
  2. Thomas K, Saadabadi A: Olanzapine . [PubMed:30422498]
  3. Flockhart Table of Drug Interactions [Link]
  4. Olanzapine FDA label [File]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
  2. Thomas K, Saadabadi A: Olanzapine . [PubMed:30422498]
  3. Rao ML, Hiemke C, Grasmader K, Baumann P: [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7. doi: 10.1055/s-2001-18381. [PubMed:11704898]
  4. SYMBYAX (olanzapine and fluoxetine HCl capsules) - FDA Label [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Trimethylamine monooxygenase activity
Specific Function
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an impor...
Gene Name
FMO3
Uniprot ID
P31513
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 3
Molecular Weight
60032.975 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
Current data regarding this enzyme inhibition is limited to in vitro studies, which is also indicated on the FDA label.
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA: In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol. 1996 Mar;41(3):181-6. [PubMed:8866916]
  2. Olanzapine FDA label [File]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Olanzapine FDA label [File]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A4
Uniprot ID
P22310
Uniprot Name
UDP-glucuronosyltransferase 1-4
Molecular Weight
60024.535 Da
References
  1. Ng C., Lin K., Singh B. and Chiu E. (2008). Ethno-psychopharmacology. Cambridge University Press. [ISBN:978-0-521-87363-5]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
The total cytochrome P450 inhibition of olanzapine is <0.3%. The ki for CYP3A mediated formation of 1'-hydroxymidazolam is is 491, with an IC50 of 14.65µM.
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA: In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol. 1996 Mar;41(3):181-6. [PubMed:8866916]
  2. Gervasini G, Caballero MJ, Carrillo JA, Benitez J: Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. ISRN Pharmacol. 2013;2013:792456. doi: 10.1155/2013/792456. Epub 2013 Feb 13. [PubMed:23476805]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
The total cytochrome P450 inhibition of olanzapine is <0.3%. The ki for CYP3A mediated formation of 1'-hydroxymidazolam is is 491, with an IC50 of 14.65µM.
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...

Components:
References
  1. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA: In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol. 1996 Mar;41(3):181-6. [PubMed:8866916]
  2. Gervasini G, Caballero MJ, Carrillo JA, Benitez J: Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. ISRN Pharmacol. 2013;2013:792456. doi: 10.1155/2013/792456. Epub 2013 Feb 13. [PubMed:23476805]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
  2. Thomas K, Saadabadi A: Olanzapine . [PubMed:30422498]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
  2. Thomas K, Saadabadi A: Olanzapine . [PubMed:30422498]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686]

Drug created on June 13, 2005 07:24 / Updated on December 11, 2019 03:25